Psoriasis and Atopic Dermatitis
|
Tralokinumab meets endpoints for all phase 3 studies
|
LEO Pharma has recently announced that all three phase 3 studies examining the safety and efficacy of the atopic dermatitis investigational drug tralokinumab met all of its primary and secondary endpoints, leading way to the company now seeking marketing authorization for the drug.
|
|
Bimekizumab offers hope for skin clearance in PsO
|
Newly published results from a phase 3 study demonstrate the superiority of bimekizumab over adalimumab for plaque psoriasis.
|